Overview

* TG Therapeutics Q2 2025 rev rises 91% yr/yr, driven by BRIUMVI sales

* Co raises 2025 BRIUMVI U.S. net revenue target to $570-$575 mln

* BRIUMVI approved in EU, UK, Switzerland, and Australia

Outlook

* TG Therapeutics ( TGTX ) raises full-year 2025 BRIUMVI U.S. revenue target to $570-$575 mln

* Company increases 2025 global revenue target to approximately $585 mln

* TG Therapeutics ( TGTX ) cites strong uptake and physician confidence in BRIUMVI

* Company sees BRIUMVI well positioned to redefine multiple sclerosis treatment expectations

Result Drivers

* BRIUMVI UPTAKE - Strong uptake and increasing physician confidence in BRIUMVI driving revenue growth, per CEO Michael S. Weiss

* LICENSE REVENUE - License, milestone, royalty and other revenue rose to $2.3 million

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $138.84

Product mln

Revenue

Q2 Net $28.19

Income mln

Q2 $34.84

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for TG Therapeutics Inc ( TGTX ) is $46.00, about 23.9% above its August 1 closing price of $35.02

* The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 36 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)